LONDON, UK: GSK plc (LSE/NYSE: GSK) has announced an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to co-promote its shingles vaccine, Shingrix, in China for an initial three-year period. The partnership aims to significantly extend the availability and access of Shingrix, which has shown 100% vaccine efficacy in preventing shingles in Chinese adults aged 50 and over.

Zhifei, the largest Chinese vaccine company by revenue, will have exclusive rights to import and distribute Shingrix in China, covering more than 30,000 vaccination points across the country. GSK, as the license holder for the product, will co-promote Shingrix by raising awareness of the importance of shingles vaccination among healthcare professionals.

The partnership is expected to generate £2.5 billion in revenue for GSK over the three-year period. The agreement also includes the option to extend the collaboration to include GSK’s novel RSV vaccine, Arexvy, upon approval in China.

Inceptive raises $100 million to revolutionize drug and vaccine design with AI